Advertisement
Advertisement
MDGL
Madrigal Pharmaceuticals, Inc. Common Stock
533.88
USDSponsored
-12.45
-2.28%
Apr 06, 16:00 UTC -4
Closed
Pre-Market
537.50
+3.62
+0.68%
MDGL Earnings Reports
Positive Surprise Ratio
MDGL beat 22 of 41 last estimates.
54%
Next Report
Date of Next Report
Apr 29, 2026
Estimate for Q1 26 (Revenue/ EPS)
$307.31M
/-$4.19
Implied change from Q4 25 (Revenue/ EPS)
-4.29%
/+63.04%
Implied change from Q1 25 (Revenue/ EPS)
+123.90%
/+26.20%
Madrigal Pharmaceuticals, Inc. Common Stock earnings per share and revenue
On Feb 19, 2026, MDGL reported earnings of -2.57 USD per share (EPS) for Q4 25, missing the estimate of -0.68 USD, resulting in a -273.98% surprise. Revenue reached 321.08 million, compared to an expected 318.74 million, with a 0.74% difference. The market reacted with a -11.11% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 13 analysts forecast an EPS of -4.19 USD, with revenue projected to reach 307.31 million USD, implying an increase of 63.04% EPS, and decrease of -4.29% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Centessa Pharmaceuticals plc - ADR
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.38
Actual
-$0.48
Surprise
-23.58%
Lexeo Therapeutics, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.32
Actual
-$0.27
Surprise
+15.84%
Galectin Therapeutics Inc.
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.10
Actual
-$0.08
Surprise
+21.57%
Unicycive Therapeutics, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.48
Actual
-$0.81
Surprise
-69.64%
Cardiol Therapeutics Inc. Class A Common Shares
Report Date
Apr 01, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.07
Surprise
+14.22%
Actinium Pharmaceuticals, Inc
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.20
Surprise
-5.04%
Jupiter Neurosciences, Inc. Common Stock
Report Date
Apr 01, 2026 For Q4 25
Estimate
-$0.07
Actual
-$0.06
Surprise
+6.16%
Scienture Holdings, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.28
Actual
-$0.11
Surprise
+61.48%
Reviva Pharmaceuticals Holdings, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$1.19
Actual
-Surprise
-
60 Degrees Pharmaceuticals, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$2.32
Actual
-$2.34
Surprise
-0.62%
FAQ
What were Madrigal Pharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Madrigal Pharmaceuticals, Inc. Common Stock reported EPS of -$2.57, missing estimates by -273.98%, and revenue of $321.08M, 0.74% above expectations.
How did the market react to Madrigal Pharmaceuticals, Inc. Common Stock's Q4 2025 earnings?
The stock price moved down -11.11%, changed from $491.49 before the earnings release to $436.87 the day after.
When is Madrigal Pharmaceuticals, Inc. Common Stock expected to report next?
The next earning report is scheduled for Apr 29, 2026.
What are the forecasts for Madrigal Pharmaceuticals, Inc. Common Stock's next earnings report?
Based on 13
analysts, Madrigal Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$4.19 and revenue of $307.31M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement